Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin lymphomas (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents approximately 60% of all CTCL, followed by Sézary syndrome (SS), approximately 5%. We retrospectively analyzed the outcome of 118 patients with MF (n=96) and SS (n=22) treated between the years 1998 and 2021 at the Charles University General Hospital in Prague, Czech Republic. The ratio between men and women was 1.2:1 (62 men, and 56 women). The median age at diagnosis was 62 years (23 to 92 years). From the MF cohort 48 patients (50% out of MF cohort) presented with advanced stage disease. Ninety patients (77%) received a systemic treatment at any time from the diagnosis; the median number of therapy lines was two. At the time of database lock, the overall survival (OS) of 96 patients with MF reached 17.7 years with the median follow-up 4.0 years. With the median follow-up 2.6 years, the median OS of 22 patients with SS was 3.5 years. The most common type of systemic therapy for MF included low-dose methotrexate (61%), interferon-alpha (58%), bexarotene (28%), and chlorambucil (25%). The most common type of therapy for SS included bexarotene (64%), extracorporeal photopheresis (50%), and interferon-alpha (45%). Only the minority of patients received innovative targeted agents including brentuximab vedotin, mogamulizumab, or pembrolizumab. Besides the retrospective analysis of the CTCL cohort, current standards and future perspectives of selected innovative agents are summarized and discussed. The analyzed cohort represents the largest cohort of CTCL patients in the Czech Republic. Overall, the survival parameters of our CTCL cohort are comparable to those previously published by other groups. In conclusion, our analysis of 118 real world cohort of consecutive CTCL patients treated at the single center confirmed the efficacy of immune response modifiers and underlines the urgent need for ample implementation of innovative agents and their combinations into earlier lines of therapy.

1st Dept of Internal Medicine Hematology University General Hospital Prague and 1st Faculty of Medicine Charles University Prague Czechia

Department of Dermatovenerology University General Hospital Prague and 1st Faculty of Medicine Charles University Prague Czechia

Institute of Hematology and Blood Transfusion Prague Czechia

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czechia

Zobrazit více v PubMed

Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. . The 2018 Update of the WHO-EORTC Classification for Primary Cutaneous Lymphomas. Blood (2019) 133(16):1703–14. doi: 10.1182/blood-2018-11-881268 PubMed DOI PMC

Polivka JMJ. ed. Epidemiology of Primary Cutaneous Lymphomas in the Czech Republic According to Data of the Czech National Cancer Registry. London: Cutaneous Lymphomas: Insight & Therapeutic Progress; (2017).

Korgavkar K, Xiong M, Weinstock M. Changing Incidence Trends of Cutaneous T-Cell Lymphoma. JAMA Dermatol (2013) 149(11):1295–9. doi: 10.1001/jamadermatol.2013.5526 PubMed DOI

Dobos G, Pohrt A, Ram-Wolff C, Lebbe C, Bouaziz JD, Battistella M, et al. . Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers (Basel) (2020) 12(10):2921. doi: 10.3390/cancers12102921 PubMed DOI PMC

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. . Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal. J Clin Oncol (2010) 28(31):4730–9. doi: 10.1200/JCO.2009.27.7665 PubMed DOI

Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, et al. . A Cutaneous Lymphoma International Prognostic Index (CLIPi) for Mycosis Fungoides and Sezary Syndrome. Eur J Cancer (2013) 49(13):2859–68. doi: 10.1016/j.ejca.2013.04.018 PubMed DOI

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. . Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol (2015) 33(32):3766–73. doi: 10.1200/JCO.2015.61.7142 PubMed DOI PMC

Sanz-Bueno J, Lora D, Monsalvez V, Maronas-Jimenez L, Postigo C, Rodriguez-Peralto JL, et al. . The New Cutaneous Lymphoma International Prognostic Index (CLIPi) for Early Mycosis Fungoides Failed to Identify Prognostic Groups in a Cohort of Spanish Patients. Br J Dermatol (2016) 175(4):794–6. doi: 10.1111/bjd.14559 PubMed DOI

Nikolaou V, Papadavid E, Patsatsi A, Siakantaris M, Economidi A, Marinos L, et al. . Prognostic Indicators for Mycosis Fungoides in a Greek Population. Br J Dermatol (2017) 176(5):1321–30. doi: 10.1111/bjd.15000 PubMed DOI

Mourad A, Gniadecki R. Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-Analysis. J Invest Dermatol (2020) 140(2):495–7.e5. doi: 10.1016/j.jid.2019.07.712 PubMed DOI

Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. . Cutaneous T Cell Lymphoma. Nat Rev Dis Primers (2021) 7(1):61. doi: 10.1038/s41572-021-00296-9 PubMed DOI

Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. . European Organisation for Research and Treatment of Cancer Consensus Recommendations for the Treatment of Mycosis Fungoides/Sezary Syndrome - Update 2017. Eur J Cancer (2017) 77:57–74. doi: 10.1016/j.ejca.2017.02.027 PubMed DOI

Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary Cutaneous Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2018) 29(Supplement_4):iv30–40. doi: 10.1093/annonc/mdy133 PubMed DOI

Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, et al. . British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines for the Management of Primary Cutaneous Lymphomas 2018. Br J Dermatol (2019) 180(3):496–526. doi: 10.1111/bjd.17240 PubMed DOI

Elsayad K, Rolf D, Sunderkotter C, Weishaupt C, Muller EC, Nawar T, et al. . Low-Dose Total Skin Electron Beam Therapy Plus Oral Bexarotene Maintenance Therapy for Cutaneous T-Cell Lymphoma. J Dtsch Dermatol Ges (2022) 20(3):279–85. doi: 10.1111/ddg.14657 PubMed DOI

Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, et al. . Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome: A Multicenter Phase II Study. J Clin Oncol (2020) 38(1):20–8. doi: 10.1200/JCO.19.01056 PubMed DOI PMC

National Comprehensive Cancer Network . Primary Cutaneous Lymphoma (2022). Available at: https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf.

Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. . Phase IIb Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma. J Clin Oncol (2007) 25(21):3109–15. doi: 10.1200/JCO.2006.10.2434 PubMed DOI

Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. . Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. J Clin Oncol (2010) 28(29):4485–91. doi: 10.1200/JCO.2010.28.9066 PubMed DOI

Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. . Brentuximab Vedotin or Physician's Choice in CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA): An International, Open-Label, Randomised, Phase 3, Multicentre Trial. Lancet (2017) 390(10094):555–66. doi: 10.1016/S0140-6736(17)31266-7 PubMed DOI

Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, et al. . Response to Brentuximab Vedotin Versus Physician's Choice by CD30 Expression and Large Cell Transformation Status in Patients With Mycosis Fungoides: An ALCANZA Sub-Analysis. Eur J Cancer (2021) 148:411–21. doi: 10.1016/j.ejca.2021.01.054 PubMed DOI PMC

Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, et al. . Randomized Phase 3 ALCANZA Study of Brentuximab Vedotin vs Physician's Choice in Cutaneous T-Cell Lymphoma: Final Data. Blood Adv (2021) 5(23):5098–106. doi: 10.1182/bloodadvances.2021004710 PubMed DOI PMC

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. . Mogamulizumab Versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC): An International, Open-Label, Randomised, Controlled Phase 3 Trial. Lancet Oncol (2018) 19(9):1192–204. doi: 10.1016/S1470-2045(18)30379-6 PubMed DOI

Cowan RA, Scarisbrick JJ, Zinzani PL, Nicolay JP, Sokol L, Pinter-Brown L, et al. . Efficacy and Safety of Mogamulizumab by Patient Baseline Blood Tumour Burden: A Post Hoc Analysis of the MAVORIC Trial. J Eur Acad Dermatol Venereol (2021) 35(11):2225–38. doi: 10.1111/jdv.17523 PubMed DOI PMC

Horwitz S, Zinzani PL, Bagot M, Kim YH, Moskowitz AJ, Porcu P, et al. . Lack of Impact of Type and Extent of Prior Therapy on Outcomes of Mogamulizumab Therapy in Patients With Cutaneous T Cell Lymphoma in the MAVORIC Trial. Leuk Lymphoma (2021) 62(13):3109–18. doi: 10.1080/10428194.2021.1953007 PubMed DOI PMC

Remák E, Hawkins N, Jones T, Otley M, Twigger R, Prince M. Understanding Relative Survival Outcomes for Patients With Cutaneous T-Cell Lymphoma (CTCL) Subtypes Mycosis Fungoides and Sézary Syndrome Treated With Mogamulizumab or Vorinostat: Combining Australian Real-World Evidence and MAVORIC Phase 3 Trial Data. Eur J Cancer (2021) 156:S18. doi: 10.1016/S0959-8049(21)00659-6 PubMed DOI

Kim YH. What Factors Guide Treatment Selection in Mycosis Fungoides and Sezary Syndrome? Hematology (2021) 2021(1):303–12. doi: 10.1182/hematology.2021000263 PubMed DOI PMC

Brumfiel CM, Patel MH, Puri P, Besch-Stokes J, Lester S, Rule WG, et al. . How to Sequence Therapies in Mycosis Fungoides. Curr Treat Options Oncol (2021) 22:101. doi: 10.1007/s11864-021-00899-0 PubMed DOI

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. . Revisions to the Staging and Classification of Mycosis Fungoides and Sezary Syndrome: A Proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood (2007) 110(6):1713–22. doi: 10.1182/blood-2007-03-055749 PubMed DOI

Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. . Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol (2011) 29(18):2598–607. doi: 10.1200/JCO.2010.32.0630 PubMed DOI PMC

Zinzani PL, Ferreri AJ, Cerroni L. Mycosis Fungoides. Crit Rev Oncol Hematol (2008) 65(2):172–82. doi: 10.1016/j.critrevonc.2007.08.004 PubMed DOI

Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-Term Outcome of 525 Patients With Mycosis Fungoides and Sezary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression. Arch Dermatol (2003) 139(7):857–66. doi: 10.1001/archderm.139.7.857 PubMed DOI

Alberti-Violetti S, Talpur R, Schlichte M, Sui D, Duvic M. Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment. Clin Lymphoma Myeloma Leukemia (2015) 15(6):e105–e12. doi: 10.1016/j.clml.2015.02.027 PubMed DOI

Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in Cutaneous T-Cell Lymphoma by Skin Stage: Long-Term Survival in 489 Patients. J Am Acad Dermatol (1999) 40(3):418–25. doi: 10.1016/S0190-9622(99)70491-3 PubMed DOI

Nawar T, Elsayad K, Muller EC, Rolf D, Moritz RKC, Bormann E, et al. . Quality of Life in Patients With Mycosis Fungoides and Sezary Syndrome Undergoing Low-Dose Total Skin Electron Beam Therapy With or Without Maintenance Therapy. J Am Acad Dermatol (2022) 86(4):889–91. doi: 10.1016/j.jaad.2021.03.025 PubMed DOI

Molloy K, Jonak C, Porkert S, Knobler R, Guenova E, Fassnacht C, et al. . An Update on Health-Related Quality of Life From the PROCLIPI Study. Eur J Cancer (2021) 156:S30. doi: 10.1016/S0959-8049(21)00681-X DOI

Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. . Lack of Durable Disease Control With Chemotherapy for Mycosis Fungoides and Sezary Syndrome: A Comparative Study of Systemic Therapy. Blood (2015) 125(1):71–81. doi: 10.1182/blood-2014-07-588236 PubMed DOI

Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, et al. . IPH4102, a First-in-Class Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma: An International, First-in-Human, Open-Label, Phase 1 Trial. Lancet Oncol (2019) 20(8):1160–70. doi: 10.1016/S1470-2045(19)30320-1 PubMed DOI

Bagot M, Kim Y, Zinzani PL, Dalle S, Beylot-Barry M, Ortiz-Romero PL, et al. . Lacutamab in Patients (Pts) With Advanced Mycosis Fungoides (MF) According to KIR3DL2 Expression: Early Results From the TELLOMAK Phase 2 Trial. Eur J Cancer (2021) 156:S20–S1. doi: 10.1016/S0959-8049(21)00664-X DOI

Moyal L, Feldbaum N, Goldfeiz N, Rephaeli A, Nudelman A, Weitman M, et al. . The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or With Doxorubicin. PloS One (2016) 11(1):e0146115. doi: 10.1371/journal.pone.0146115 PubMed DOI PMC

Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. . Activity of the PI3K-Delta,Gamma Inhibitor Duvelisib in a Phase 1 Trial and Preclinical Models of T-Cell Lymphoma. Blood (2018) 131(8):888–98. doi: 10.1182/blood-2017-08-802470 PubMed DOI PMC

Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, et al. . Results of an Open-Label Multicenter Phase 2 Trial of Lenalidomide Monotherapy in Refractory Mycosis Fungoides and Sezary Syndrome. Blood (2014) 123(8):1159–66. doi: 10.1182/blood-2013-09-525915 PubMed DOI

Boonstra PS, Polk A, Brown N, Hristov AC, Bailey NG, Kaminski MS, et al. . A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas. Am J Hematol (2017) 92(12):1287–94. doi: 10.1002/ajh.24895 PubMed DOI PMC

Horwitz S, Moskowitz A, Mehta-Shah N, Jacobsen E, Khodadoust M, Ganesan N, et al. . The Combination Of Duvelisib And Romidepsin (Dr) Is Highly Active Against Relapsed/Refractory Peripheral T-Cell Lymphoma With Low Rates Of Transaminitis: Final Results. Hematological Oncol (2021) 39:100–1. doi: 10.1002/hon.56_2879 DOI

Andrews JM, Schmidt JA, Carson KR, Musiek AC, Mehta-Shah N, Payton JE. Novel Cell Adhesion/Migration Pathways are Predictive Markers of HDAC Inhibitor Resistance in Cutaneous T Cell Lymphoma. EBioMedicine (2019) 46:170–83. doi: 10.1016/j.ebiom.2019.07.053 PubMed DOI PMC

Zhang P, Zhang M. Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma. Front Oncol (2021) 11:663961. doi: 10.3389/fonc.2021.663961 PubMed DOI PMC

Cristofoletti C, Narducci MG, Russo G. Sezary Syndrome, Recent Biomarkers and New Drugs. Chin Clin Oncol (2019) 8(1):2. doi: 10.21037/cco.2018.11.02 PubMed DOI